Bupropion Hydrobromide

Inquiry

Cat Number

API0232137

CAS Number

905818-69-1

If you have any other questions, please contact our experts.

Product Detail Description Scientific Support Customer Q&A

CAS Number

905818-69-1

EINECS

111-003-2

Storage

Store at room temperature

Synonyms

Aplenzin; bupropion HBr; Aplenzin ER; UNII-E70G3G5863; BVF-033; E70G3G5863; BUPROPION HYDROBROMIDE

Molecular Formula

C13H19BrClNO

Molecular Weight

320.65

Smiles

CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C.Br

Appearance

White to off-white crystalline powder

General Description

Bupropion hydrobromide is the hydrobromide salt of bupropion, a monocyclic aminoketone antidepressant structurally unrelated to selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants. The parent compound contains a chlorophenyl and a tert‑butylamino group. The hydrobromide salt alters solubility and dissolution characteristics compared to the more common hydrochloride salt.

Mechanism of Action

Bupropion acts as a selective inhibitor of norepinephrine and dopamine reuptake (NDRI) without significant direct effects on serotonin, histamine, or cholinergic receptors. It also antagonizes nicotinic acetylcholine receptors, contributing to its smoking‑cessation efficacy. The dual reuptake inhibition enhances noradrenergic and dopaminergic tone in brain regions regulating mood, reward, and attention.

Application

Bupropion is indicated for major depressive disorder, seasonal affective disorder, and as an adjunct for smoking cessation. It is also used off‑label for attention‑deficit/hyperactivity disorder (ADHD) and for treating antidepressant‑induced sexual dysfunction. Unlike SSRIs, it does not cause weight gain or sexual side effects, but it lowers seizure threshold.

In a multisite double‑blind sequential parallel comparison trial (403 participants), extended‑release injectable naltrexone (380 mg every 3 weeks) plus oral extended‑release bupropion (450 mg/day) for 12 weeks produced a weighted average response (≥3 methamphetamine‑negative urine samples out of 4) of 13.6% compared to 2.5% with placebo, a significant treatment effect of 11.1 percentage points (P<0.001). Adverse events included gastrointestinal symptoms, tremor, malaise, hyperhidrosis, and anorexia; serious events occurred in 3.6%. The combination was effective but the absolute response rate was low.

Fig. 1 Responses and Methamphetamine-Negative Urine Samples. (Trivedi MH, et al., 2021)

References

Trivedi MH, et al. Bupropion and Naltrexone in Methamphetamine Use Disorder. N Engl J Med. 2021;384(2):140-153.

Does Bupropion Hydrobromide require protection from light during storage?

Yes, it is photosensitive. UV light can cause photodegradation and discoloration. Store in light-resistant containers, preferably amber glass or original packaging.

What is the recommended storage temperature for Bupropion Hydrobromide?

Store at controlled room temperature (15-25°C). Avoid excessive heat above 30°C, which can accelerate degradation to m-chlorobenzoic acid and other impurities.

Is Bupropion Hydrobromide stable in extended-release tablet formulations?

Yes, when formulated with moisture-protective coatings and packaging.

How is the impurity 3-chlorobenzoic acid (a hydrolytic degradation product) monitored?

This degradation product is quantified using a stability-indicating HPLC method, ensuring it remains below ICH qualification thresholds.